What Performance Characteristics And Therapeutic Benefits Does A 1540 Nm Er:glass Laser Provide For Facial And Body Acne Treatment Across Various Skin Phototypes? Discover The Efficacy And Safety Of This Non-Ablative Laser For Acne.

A 1540 nm Er:Glass laser is a non-ablative, dermally penetrating treatment that can reduce facial and truncal acne while preserving the epidermis. Clinical studies report approximately 78%–82% reductions in acne lesion counts across Fitzpatrick skin phototypes I–IV after a treatment series, with additional benefits including reduced oiliness, improved inflammatory lesions, and remission lasting months to years in some studies. Integrated cooling generally improves comfort and may allow treatment without topical anesthesia.

The main value of 1540 nm Er:Glass is its combination of deep sebaceous-gland targeting, surface preservation, clinical efficacy, and relatively low downtime. It is particularly useful when acne affects large areas such as the back or chest, although treatment settings must be individualized by skin type and disease severity.

How the 1540 nm Er:Glass Laser Works

Non-ablative dermal heating

The laser targets water within the dermis rather than vaporizing the skin surface. This creates controlled micro-thermal injury while keeping the epidermis largely intact.

The resulting thermal response initiates collagen remodeling and can temporarily or persistently alter the activity and structure of the pilosebaceous unit.

Effects on sebaceous glands

Thermal energy reaches the dermal sebaceous glands and can reduce their activity. Lower sebum production helps address one of the biological drivers of acne development.

Some clinical and biopsy findings also describe longer-term sebaceous-gland miniaturization or rarefaction, which may help explain sustained improvement after the treatment series ends.

Treatment depth and coverage

The 1540 nm wavelength is designed to deliver energy into the dermis, with reported treatment depths of approximately 0.4 to 2.0 mm, depending on the system and settings.

Because the treatment is not limited to small superficial lesions, it can be used on the face, back, chest, and other larger acne-prone areas.

Expected Acne Benefits

Reduction in active lesions

Clinical evaluations report approximately 78%–82% reductions in facial and back acne lesion counts after a course of treatments.

Improvement may include inflammatory papules, pustules, and deeper nodular lesions, although outcomes vary with acne severity, treatment parameters, and patient biology.

Reduced skin oiliness

Patients commonly report a noticeable reduction in cutaneous oiliness. This is a direct practical benefit of suppressing sebaceous-gland activity.

Reduced oil production may also make maintenance skincare easier and reduce the greasy appearance associated with seborrheic or acne-prone skin.

Longer-term remission

Some studies report acne clearance sustained for up to two years after treatment. This suggests that the effect is not limited to short-term surface inflammation.

However, remission is not guaranteed. Hormonal influences, skincare practices, medication use, and the underlying severity of acne continue to affect recurrence risk.

Potential textural improvement

Because the treatment induces dermal remodeling, it may also improve pore appearance and atrophic acne-scar texture in suitable patients.

This should be considered a secondary benefit rather than a substitute for a dedicated acne-scar treatment plan.

Performance Across Skin Phototypes

Evidence in Fitzpatrick types I–IV

Clinical studies summarized in the reference material include patients across Fitzpatrick skin types I–IV, with meaningful lesion-count reductions reported across this range.

The treatment’s non-ablative design preserves the epidermis, which is important when treating patients for whom epidermal injury could increase recovery time or pigmentary complications.

Melanin-related considerations

At 1540 nm, treatment is primarily directed toward dermal water rather than relying on strong melanin absorption. This can reduce the extent to which epidermal pigment competes with the intended target.

That characteristic supports its use across a broad range of skin tones, but it does not eliminate pigmentary risk. Darker or recently tanned skin still requires conservative parameter selection, appropriate cooling, and careful monitoring.

Safety expectations

The reported clinical profile includes minimal immediate or delayed adverse effects and a low incidence of post-inflammatory hyperpigmentation in the cited studies.

Individual risk remains dependent on fluence, pulse duration, density, cooling, recent sun exposure, active inflammation, and the patient’s history of abnormal pigmentation.

Practical Treatment Characteristics

Typical treatment course

Clinical protocols commonly use approximately four sessions, spaced either biweekly or monthly depending on the device and treatment plan.

Improvement is assessed over time rather than immediately after one session because sebaceous-gland alteration, inflammation reduction, and collagen remodeling develop progressively.

Patient comfort

Integrated sapphire or contact cooling, sometimes set near 5°C, protects the epidermis and reduces the sensation of heat.

Compared with some 1450 nm diode and 1320 nm Nd:YAG approaches, 1540 nm Er:Glass treatment is generally associated with lower treatment discomfort and may not require topical anesthesia.

Downtime and treatment access

The intact epidermis typically supports limited downtime compared with ablative resurfacing. This can improve patient compliance, particularly when multiple facial or body areas require treatment.

Large treatment areas such as the back and chest can also be addressed without the logistical burden associated with lesion-by-lesion procedures.

Understanding the Trade-offs

Results are not instantaneous

The laser does not provide an immediate cure for acne. Patients generally need a treatment series, and the full benefit may become clearer several weeks or months after the final session.

Efficacy varies by patient

The reported 78%–82% lesion reduction is a clinical-study range, not a guaranteed individual outcome. Severe nodulocystic acne, untreated hormonal drivers, scarring, or inconsistent skincare may reduce the response.

Non-ablative does not mean risk-free

Although the epidermis is preserved, excessive energy or inadequate cooling can still produce erythema, edema, burns, prolonged inflammation, or pigmentary change.

Treatment should therefore be performed with validated device protocols and settings tailored to phototype, tanning status, acne activity, and treatment area.

It may not replace medical acne management

The laser primarily addresses dermal inflammation and sebaceous-gland activity. Some patients still require topical therapy, systemic medication, hormonal management, or other interventions.

A comprehensive plan is especially important for recurrent, scarring, or hormonally driven acne.

Making the Right Choice for Your Goal

The laser is most appropriate when the clinical objective is meaningful acne reduction with limited epidermal disruption.

If your primary focus is reducing inflammatory facial acne: A course of 1540 nm Er:Glass treatments can target sebaceous-gland activity and reduce papules, pustules, and deeper lesions while preserving the skin surface.
If your primary focus is treating back or chest acne: Its dermal penetration and ability to cover larger areas make it a practical option for truncal disease.
If your primary focus is minimizing downtime: Non-ablative delivery and integrated cooling generally provide a more comfortable recovery than ablative resurfacing.
If your primary focus is treating patients across diverse phototypes: The wavelength and epidermal-sparing design support use across Fitzpatrick I–IV, but darker or tanned skin still requires individualized settings and pigment-risk management.
If your primary focus is long-term oil control or remission: The treatment may reduce sebaceous activity for an extended period, but maintenance care and management of underlying acne drivers remain important.

Overall, 1540 nm Er:Glass offers a strong balance of acne efficacy, sebaceous-gland control, comfort, and epidermal preservation when applied through an individualized treatment protocol.

Summary Table:

Performance Characteristic	Therapeutic Benefit
Non-ablative dermal heating	Preserves epidermis, reduces downtime
Sebaceous gland targeting	Reduces oiliness and acne lesions
Depth 0.4-2.0 mm	Treats face, back, chest effectively
78%-82% lesion reduction	Significant acne improvement
Suitable for skin types I-IV	Safe across diverse phototypes

Ready to enhance your clinic's acne treatment offerings? BELIS provides professional-grade 1540 nm Er:Glass lasers and a full range of aesthetic equipment. Contact us today to learn how our advanced technology can benefit your practice and patients. Contact us for more information.